Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Empagliflozin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00881530 ↗ Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension Completed Boehringer Ingelheim Phase 2 2009-03-01 The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
NCT00885118 ↗ 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM) Completed Boehringer Ingelheim Phase 2 2009-04-01 The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
NCT01001962 ↗ Double Blind Placebo Study of JARDIANCE┬« (Empagliflozin) in Prehypertensives Type II Diabetics Unknown status Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01111318 ↗ Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function Completed Boehringer Ingelheim Phase 1 2010-07-01 The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin

Condition Name

Condition Name for Empagliflozin
Intervention Trials
Diabetes Mellitus, Type 2 57
Healthy 31
Heart Failure 19
Type 2 Diabetes Mellitus 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Empagliflozin
Intervention Trials
Diabetes Mellitus 120
Diabetes Mellitus, Type 2 113
Heart Failure 32
Kidney Diseases 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Empagliflozin

Trials by Country

Trials by Country for Empagliflozin
Location Trials
United States 717
Canada 144
Germany 64
Australia 36
Japan 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Empagliflozin
Location Trials
Texas 42
Florida 35
California 34
Ohio 29
New York 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Empagliflozin

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin
Clinical Trial Phase Trials
Phase 4 75
Phase 3 59
Phase 2/Phase 3 7
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Empagliflozin
Clinical Trial Phase Trials
Completed 128
Recruiting 48
Not yet recruiting 37
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Empagliflozin

Sponsor Name

Sponsor Name for Empagliflozin
Sponsor Trials
Boehringer Ingelheim 100
Eli Lilly and Company 50
University Hospital, Basel, Switzerland 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Empagliflozin
Sponsor Trials
Other 262
Industry 187
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.